Group items tagged

A community pharmacist was applauded for his 'quick-thinking' action in treating a Co Down woman with a fatal bee sting. Joan Johnson, from Moira, was stung on her scalp in her home garden. After the bite, she noticed allergic reactions on her neck and ears with severe itching and redness. However, she was advised to visit her local pharmacy by the GP where the pharmacist, Stephen Joyce, quickly administered life-saving antihistamine and an adrenaline injection while an ambulance was called. Joan hailed the 'treatment' and the 'professionalism' of the whole team for saving her life. "What was just a simple bee-sting, quickly became something very serious. On arrival at the pharmacy on the advice from my GP, I was dealt with very promptly and Stephen was summoned and immediately took control of the situation. "I was given an urgent antihistamine, but quickly started feeling lightheaded and faint. The pharmacy team assisted me to a chair and called an ambulance," she said.

wanna have baby quickly follow this way

Lose weight quickly with the Slimming Jab at Olive Health & Travel Clinic. It also appears to improve many indicators of cardiovascular risk.

The mandate to the healthcare industry is clear: nurture an environment of respect and professionalism. Institutions should promote the message that sexual harassment is not only prohibited, but shunned. They must build reporting structures that value input without retribution or recrimination, act quickly and definitively on complaints brought forward, and provide remedies that satisfy the parties involved and the institution overall.

We offer best Large mung beans for sprouting for your own kitchen and home. Seeds for Bean sprouts are nutritious and delicious. Mung beans are quickly digested because they grow with their own digestive enzymes. Full of vitamins, proteins, nutrients, fiber. It's quick and easy. Order online or call us on 0116 278 4449.

I have always been passionate about Community Pharmacy and am proud of the way that the sector navigated itself through Covid-19 and is currently navigating itself through all the changes in the NHS landscape. When I started my role in Sep 2019 as the CEO of Kent LPC, I used to say that community pharmacy has changed more in the last five years than the 15 before that, however, I now believe community pharmacy has changed more in the last two years than the 20 before. The year 2019 saw the start of the five-year Community Pharmacy Contractual Framework which set out how community pharmacy would support delivery of the NHS long term plan. What PSNC (or any of us) when negotiating this deal had not envisaged was the Covid-19 pandemic. Whilst the world turned upside down, we saw high street shops close their doors and immense pressure flood the NHS. Community pharmacy did what they always do, they adapted, teams came together, worked through, and showed resilience in the face of adversity. In Kent, I saw us integrate into primary are and into the NHS structure very quickly, in the first few weeks after Covid-19. All the usual red tape was removed, we all worked together to implement services to help patients in a matter of weeks when they would have normally taken months.

Walgreens Boots Alliance, the parent company of Boots UK, has begun a strategic review of its business in the United Kingdom, chief executive officer Rosalind Brewer said on Tuesday (January 11) - as the pharmacy chain tries to renew its focus on US healthcare. Boots has over 2,200 stores across the UK, which include pharmacies, health and beauty stores, among others, according to the chain's website. "This review is very much in line with our renewed priorities and strategic direction. In particular, our increased focus on US healthcare. While the process is at an exploratory stage, we do expect to move quickly," Brewer said at the JP Morgan Healthcare Conference. The review comes at a time when the company, which was formed in 2014 after the acquisition of stake in Alliance Boots by Walgreens, moves beyond its drugstores with its investments in two smaller healthcare providers, CareCentrix and VillageMD.

The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed. Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent after more research in the coming weeks. "It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio. But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly." In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".

Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise. The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa. Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England. Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last. But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people. "These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.

Kate Bingham, the former head of the UK's Covid-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus. Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy. "The question is do they have the same level of efficacy?" she said on Wednesday. Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants. "It's not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don't," she said.

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

Growing up with a family that worked in pharmacy, our dinner time conversation was not like that of other families. Ours would centre around medicines, prescriptions, and the health challenges within our local community. I quickly came to understand the importance of the role played by community pharmacists. So I can't help but be concerned that the current direction being taken by digital health innovation threatens to leave community pharmacies behind. Whilst it is brilliant that patients can easily access their prescriptions through the rise of online pharmacies, many of these cut out the vital knowledge and expertise of local community pharmacists, and threaten to end the traditional close ties between local community pharmacists and their patients. Nine out of 10 NHS users believe that pharmacists play an unrivalled role when it comes to keeping patients in the community safe. We must ensure that digital health does not replace this important source of advice for health problems and injuries, but instead preserves and enhances this vital, personal role and enables pharmacists to continue delivering care in new and effective ways. A vital connection with patients Community pharmacies provide crucial support to local patients with managing their medicines safely, particularly older and more vulnerable people. The specific expertise and knowledge held by pharmacists can help inform the long-term management of a patient's condition and ensure they are kept safe from potential side effects and complications.

There is no doubt that the pandemic has changed the way healthcare professionals work within the primary care setting. The advent of Covid-19 meant that we all had to rapidly modify the way we supported and met the needs of patients, some of whom saw the services they usually took for granted, virtually cease overnight. There are around 15 million people in England living with long-term health conditions including asthma. These people have the greatest healthcare needs of the whole population with 50 per cent of all GP appointments and 70 per cent of all bed days taken by this cohort of patients, and their treatment and care absorbing 70 per cent of acute and primary care budgets in England. This situation isn't going to improve any time soon. In the past, most people had a single condition, today multi-morbidity is becoming the norm. At the start of the pandemic, the Royal College of General Practice and British Medical Association issued guidance to practices on prioritising workload. This included the importance of maintaining long-term condition reviews in asthma, COPD and diabetes, along with appropriate transition of at-risk warfarin patients. These reviews were deemed as essential workstreams for patients considered to be at high risk. Traditionally, the unique skills set of a pharmacist has meant that we have played a major role in supporting these patients. I work with a team of over 90 clinical pharmacists who, in partnership with individual practices, PCNs, CCGs and STPs, help with the long-term management of people with chronic conditions. But the onset of Covid-19 meant that we now had to plug a potential gap in service provision, and quickly.

What skills does a pharmacist need these days? You'd think it would be sufficient to have a good understanding of pharmacy and the ability to offer a great patient service. Whilst this is true of course, the reality of the day to day role demands skills which most pharmacists have not been trained for as part of their formal qualification. At the very least, pharmacists find themselves responsible for running the pharmacy, managing people, managing processes and dealing with issues relating to customers, suppliers, surgeries, regulators and stakeholders. Even the most junior pharmacists quickly find themselves being accountable for the financial performance of their department and having to work within budgets or deliver on targets. Remarkably, despite the apparent lack of any formal training in these areas, pharmacists have been able to adapt and meet the challenges of whatever their job has thrown at them. Many pharmacists go even further, bringing out their inner entrepreneurial spirit to set up their own business. There are now over 6,000 pharmacy businesses owned by independent pharmacists, with this segment growing. Whilst pharmacists have historically adapted to their environments and picked up the necessary business skills, the rapidly changing landscape of pharmacy will require pharmacists to establish new skills to help ensure their businesses survive and thrive.

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men, particularly during and after the menopause. According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from the condition, but only once they have had the symptoms of dry eye syndrome described to them. Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be. Causes of dry eye Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated, dry eyes can even lead to long-term damage and sight problems. Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye. However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers: fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers can cause dry eyes.

A recent Pharmacists' Defence Association (PDA) survey revealed that 80 per cent of its member working in the NHS in England, Wales, and Northern Ireland rejected the NHS pay award. "For the first time in the history of our union, members have told us they are so angry that they would not rule out industrial action in conjunction with other NHS unions," said Paul Moloney, PDA Union national officer. "It is important that, whoever is to lead the government, they listen to this message and act now to ensure our members and others in the NHS do not face swinging cuts to their standard of living." PDA members were asked whether they would support industrial action if they had rejected the award and if other NHS unions would be taking industrial action. 58 per cent of those responding said they would support the PDA Union taking industrial action if members of other unions were also planning to take action on this issue. For now, however, the PDA Union will wait for other unions to publish the outcomes of their own consultations. As a union dedicated to representing the needs of only pharmacists, the PDA has been able to quickly survey members immediately after the pay award was announced.

Alitam has announced that it has merged with clinical skills training provider MHRx to upskill UK pharmacists so that its chain of community pharmacies in the UK can diagnose and treat minor medical ailments "quickly and safely". This is a second merger deal announced by the group that has 100-plus pharmacies, just days after its merger with Pharmadoctor to "radically transform the UK and Ireland's community pharmacy sector" into a truly preventative healthcare system. Following the merger with MHRx, Alitam will now be providing a career development platform for its pharmacy teams, which also include nurses and other healthcare professionals. MHRx's training incorporates every aspect of general practice alongside relevant topics including making appropriate patient consultation records in line with NHS guidelines. This, Alitam believes, will allow community pharmacies to carry out formal diagnoses, formulate differential diagnosis plans, and perform full clinical examinations. According to the founder and CEO Feisal Nahaboo, mergers such as these will lead to "a healthcare revolution predicated on building the world's first truly preventative healthcare model".

In partnership with Oxford University Press, the Royal Pharmaceutical Society (RPS) has launched the 'RPS Pharmacy and Pharmacology' reports. RPS Pharmacy and Pharmacology Reports is a new, fully open access journal and the sister journal to Journal of Pharmacy & Pharmacology. The journal is edited by Professor Dennis Douroumis, professor in Pharmaceutical Technology and Process Engineering at the University of Greenwich. RPS said: "The journal aims to create a truly interdisciplinary forum for members of the pharmacy, pharmacology, chemistry, biochemistry, physiology, and microbiology communities alike to come together to develop life-changing medicines of the future. The journal prioritises scientifically sound results from pharmacy and pharmacology researchers across the world." The journal operates a rapid review and publication process to ensure impactful research is disseminated as quickly as possible. All RPS members are eligible to receive a 20 per cent discount on the article processing charge.

If you have asthma, it's important to know when you should see a doctor about an asthma flare-up. A flare-up is a sudden increase in your symptoms, which can include coughing, wheezing, chest tightness, and shortness of breath. Flare-ups can be mild or severe, and they can occur at any time. If you're not sure whether you're having a flare-up, here are six obvious signs that it might be time to see a doctor. 1. YOU'RE USING YOUR INHALER MORE THAN USUAL If you have asthma, you likely have a rescue inhaler that you use when you're having symptoms. This inhaler contains a medication that can quickly relieve your symptoms. If you find that you're using your rescue inhaler more often than usual, it could be a sign that your asthma is getting worse and you need to see a doctor. By seeking a doctor near me online, you can find a reputable physician who will accurately diagnose and treat your asthma. Always look for a second opinion, as one doctor's opinion might differ from others. For example, some doctors might recommend that you use a daily inhaler, while others might only recommend using it when you're having symptoms.